Balazs Halmos, MD, answers questions for him sent in to OncLive's social media accounts on Twitter, LinkedIn, and Instagram.
Ask Me Anything
Advertisement
Joshua Richter, MD, answers questions for him sent in to OncLive's social media accounts on Twitter, LinkedIn, Instagram, and Facebook.
Maurie Markman, MD, answers questions for him sent in to OncLive's social media accounts on Twitter, LinkedIn, Instagram, and Facebook.
Advertisement
Advertisement
Trending on OncLive
1
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
4
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
5